Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis

Calcified Tissue International

Volumn 65, Issue 5, 1999, Pages 359-364

  Gonnelli, S ^a   Cepollaro, C ^b   Pondrelli, C ^b   Martini, S ^b   Montagnani, A ^b   Monaco, R ^b   Gennari, C ^b  

^a Patologia Speciale Medica   (Italy)

^b NONE

Author keywords

Alendronate; Bone mass; Bone turnover; Postmenopausal osteoporosis

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; CALCIUM CARBONATE; GLUCONOLACTATE CALCIUM; HYDROXYPROLINE; MEDRONATE TECHNETIUM TC 99M; MEDRONIC ACID; OSTEOCALCIN; PYRIDINOLINE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUMBAR SPINE; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RADIUS; RANDOMIZED CONTROLLED TRIAL; VERTEBRA;

ADULT; AGED; ALENDRONATE; BONE DENSITY; BONE REMODELING; CALCIUM; DENSITOMETRY, X-RAY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; TIME FACTORS;

EID: 0032717015     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002239900713     Document Type: Article

References (33)

1. Anonymous (1994) Consensus Development Conference. Diagnosis, prevention and treatment of osteoporosis. Am J Med 94:646-650
2. Ross PD (1996) Osteoporosis: frequency, consequences and risk factors. Arch Intern Med 156:1399-1411
3. Dempster DW, Lindsay R (1993) Pathogenesis of osteoporosis. Lancet 341:797-800
4. Marcus R (1996) The nature of osteoporosis. J Clin Endocrinol Metab 81:1-5
5. Nordin BEC, Polley KJ (1987) Metabolic consequences of the menopause. A cross-sectional, longitudinal, and intervention study on 577 normal postmenopausal women. Calcif Tissue Int 41(suppl 1):1-58
6. Parfitt AM (1988) Bone remodelling: relationship to the amount and structure of bone, and the pathogenesis and prevention of fractures. In: Riggs BL, Melton LJ III (eds) Osteoporosis. Raven Press, New York, pp 45-94
7. Riggs BL, Melton LJ III (1992) The prevention and treatment of osteoporosis. N Engl J Med 327:620-627
8. Lindsay R (1996) Estrogens and osteoporosis: clinical. In: Papapoulos SE, Lips P, Pols HAP, et al. (eds) Osteoporosis. Elsevier, Amsterdam, pp 251-256
9. Christiansen C (1996) Bisphosphonates. In: Papapoulos SE, Lips P, Pols HOP et al. Osteoporosis. Elsevier, Amsterdam, pp 291-298
10. Fleisch H (1995) Bisphosphonates in bone disease. From the laboratory to the patient. The Parthenon Publishing Group, New York-London
11. Jeal W, Barradell LB, McTavish (1997) Alendronate. A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis. Drugs 53:415-434
12. Guy JA, Shea M, Peter CP, Morrissey R, Hayes WC (1993) Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties. Calcif Tissue Int 53:283-288
13. Balena R, Toolan BC, Shea M, Markatos A, Myers ER, Lee SC, Opas EE, Seedor JG, Klein H, Frankenfield D (1993) The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 92:2577-2586
14. Garnero P, Shin WJ, Ginetys E, Karpf DB, Delmas PD (1994) Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700
15. Rossini M, Gatti D, Zamberlan N, Braga V, Dorizzi R, Adami S (1994) Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res 9:1833-1837
16. Chesnut CH III, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD, Kher U, Pryor-Tillotson S, Santora AC (1995) Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 99:144-152
17. Adami S, Passeri M, Ortolani S, Broggini M, Carratelli L, Caruso I, Gandolini G, Gnessi L, Laurenzi M, Lombardi A, Norbiato G, Pryor-Tillotson S, Reda C, Romanini L, Subrizi D, Wei L, Yates AJ (1995) Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 17:383-390
18. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah R, Hirsch LJ, Karpf DB, for the Alendronate Phase III Osteoporosis Treatment Study Group (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333: 1437-1443
19. Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora II AC, for the U.S. Alendronate Phase III Osteoporosis Treatment Study Group (1996) Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 101:488-501
20. Devogelaer JP, Broll H, Correa-Rotter R, Cumming DC, Nagant De Deuxchaisnes C, Geunsen P, Hosking D, Jaeger P, Kaufman JM, Leite M, Leon J, Liberman U, Menkes CJ, Meunier PJ, Reid I, Rodriguez J, Romanowicz A, Seeman E, Vermeulen A, Hirsch LJ, Lombardi A, Plezia K, Santora AC, Yates AJ, Yuan W (1996) Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 18:141-150
21. Bone HG, Downs RW Jr, Tucci JR, Harris ST, Weinstein RS, Licata AA, McClung MR, Kimmel DB, Gertz BJ, Hale E, Polvino WJ, for the Alendronate Elderly Osteoporosis Study Centers (1997) Dose-response relationships for alendronate treatment in osteoporotic elderly women. J Clin Endocrinol Metab 82:265-274
22. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE, for the Fracture Intervention Trial Research Group (1996) Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541
23. Hosking D, Chilvers C, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M, Yates J (1998) Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 338:485-492
24. Whyte MP, Berfeld MA, Murphy WA, Avioli LV, Teitelbaum SL (1982) Postmenopausal osteoporosis. A heterogeneous disorder as assessed by histomorphometric analysis of iliac crest bone from untreated patients. Am J Med 72:193-202
25. Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C (1988) Bone turnover in postmenopausal osteoporosis: effect of calcitonin treatment. J Clin Invest 82:1268-1274
26. Gonnelli S, Cepollaro C, Pondrelli C, Martini S, Monaco R, Gennari C (1997) The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis. J Bone Miner Res 12:624-631
27. WHO Study Group (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organization, Geneva, pp 1-129
28. 99mTc diphosphonate excretion as a simple method to quantify bone metabolism. Scand J Clin Lab Invest 44:105-109
29. Prockop DJ, Udenfriend S (1960) A specific method for the analysis of hydroxyproline in tissues and urine. Anal Biochem 1:228-239
30. Hirsch L, Watts N, McIlwain H, et al. Efficacy of alendronate to increase BMD is similar irrespective of baseline bone turnover, BMD and age. J Bone Miner Res 10(suppl 1):S350
31. Parfitt AM (1980) Morphologic basis of bone mineral measurements: transient and steady state effects of treatment in osteoporosis. Miner Electrolyte Metab 4:273-287
32. Kanis JA, Gertz BJ, Singer F, Ortolani S (1995) Rationale for the use of alendronate in osteoporosis. Osteoporosis Int 5: 1-13
33. Orr-Walker B, Wattie DJ, Evans MC, Reid IR (1997) Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in postmenopausal osteoporosis. Clin Endocrinol 46:87-92